Demystifying PROCEPT BioRobotics: Insights From 4 Analyst Reviews
Portfolio Pulse from Benzinga Insights
PROCEPT BioRobotics (NASDAQ:PRCT) has been analyzed by four analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $44.5, with a high of $50.00 and a low of $37.00, indicating a slight increase from the previous target of $44.00. Analysts from Wells Fargo and Truist Securities have raised their price targets, while Leerink Partners announced a new target. PROCEPT is a surgical robotics company with a focus on urology, and despite its revenue growth of 72.5%, it faces challenges with a net margin of -70.14% and an ROE of -10.82%.
January 09, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have updated their ratings and price targets for PROCEPT BioRobotics, with an average 12-month price target of $44.5. The company has shown strong revenue growth but struggles with profitability.
The updated analyst ratings and raised price targets suggest a positive outlook for PRCT in the short term, despite underlying profitability issues. The strong revenue growth rate is a positive indicator, but investors should be cautious of the high net margin losses and low ROE. The confidence in the impact is high due to the direct correlation between analyst ratings and stock performance, especially when multiple analysts from reputable firms adjust their targets upwards.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100